STOCK TITAN

Opthea Ltd Stock Price, News & Analysis

OPT Nasdaq

Welcome to our dedicated page for Opthea news (Ticker: OPT), a resource for investors and traders seeking the latest updates and insights on Opthea stock.

Opthea Ltd (ASX:OPT) is a clinical-stage biopharmaceutical company developing innovative therapies for retinal diseases, with its lead candidate OPT-302 targeting VEGF-C and VEGF-D pathways. This page provides investors and stakeholders with timely updates on clinical trial progress, regulatory milestones, and corporate developments.

Access comprehensive coverage of Opthea's press releases, including updates on phase 1/2a trials for wet AMD treatment, intellectual property advancements, and strategic collaborations. Our curated news feed ensures you stay informed about key events influencing the company's trajectory in ocular therapeutics.

Discover updates across multiple categories including clinical research breakthroughs, financial results, patent filings, and executive leadership announcements. All content is verified through primary sources to maintain accuracy and compliance with financial disclosure standards.

Bookmark this page for streamlined access to Opthea's latest developments. Check back regularly for real-time updates on this pioneering biotechnology firm's progress in addressing unmet needs in retinal disease treatment.

Rhea-AI Summary

Opthea (ASX/NASDAQ:OPT), a clinical-stage biopharmaceutical company focused on developing treatments for retinal diseases including wet age-related macular degeneration, has announced its participation in the Citi 2024 Global Healthcare Conference. CEO Fred Guerard will conduct one-on-one investor meetings and participate in a panel titled 'Eyes Wide Open on Ophthalmology' on December 5, 2024, at 1:45 PM ET in Miami, Florida. The presentation will be available for viewing on the company's website in the Events & Presentations section.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
conferences
-
Rhea-AI Summary

Opthea (ASX/NASDAQ: OPT) announced the appointment of Kathy Connell as Non-Executive Director to its Board, effective November 15, 2024. Connell brings extensive commercial and business development expertise across healthcare industries. The appointment comes as Opthea prepares for Phase 3 wet AMD topline data expected in 2025. Simultaneously, Megan Baldwin retired from the Board as Executive Director but will continue as Founder and Chief Innovation Officer. Connell currently serves as Senior Client Partner at Korn Ferry and holds board positions at Avecho Biotechnology, Proto Axiom, and BioNSW.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.14%
Tags
management
-
Rhea-AI Summary

Opthea (ASX/NASDAQ: OPT) announced its participation in two major ophthalmology conferences where sozinibercept will be featured. At the 17th Congress of APVRS, Dr. Gregg T. Kokame will present Phase 2b trial data showing that patients with polypoidal choroidal vasculopathy treated with a combination of sozinibercept and ranibizumab achieved significantly better visual and anatomic outcomes compared to ranibizumab alone at 24 weeks. Additionally, CEO Frederic Guerard will present at the Ophthalmology Innovation Summit XIV during the Retina Innovation Showcase.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
none
Rhea-AI Summary

Opthea (ASX/NASDAQ: OPT), a clinical-stage biopharmaceutical company focused on developing therapies for retinal diseases including wet AMD, has announced its participation in two upcoming investor conferences in November 2024. The company will present at the Virtual Bell Potter Healthcare Conference on November 18, 2024, at 3:00 PM AEDT, with CEO Frederic Guerard delivering the presentation. Additionally, Guerard will participate in one-on-one meetings at the Jefferies London Healthcare Conference on November 19, 2024. The Bell Potter presentation will be available for viewing in the Investor Relations section of Opthea's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
conferences
-
Rhea-AI Summary

Opthea (ASX/NASDAQ: OPT), a clinical-stage biopharmaceutical company developing therapies for retinal diseases, has filed its Notice of Annual General Meeting. Dr. Megan Baldwin, Executive Director, will retire from the Board at the conclusion of the annual general meeting on November 15, 2024, and has chosen not to seek re-election. Dr. Baldwin will continue her role as Founder and Chief Innovation Officer, focusing on advancing Opthea's innovation agenda.

The company is approaching anticipated sozinibercept wet AMD Phase 3 data readouts in 2025. Dr. Baldwin expressed pride in sozinibercept's potential as a breakthrough for wet AMD patients. Chairman Jeremy Levin acknowledged Dr. Baldwin's valuable contributions to the Board. Opthea is currently seeking a new director to fill the upcoming Board vacancy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.46%
Tags
none
-
Rhea-AI Summary

Opthea (ASX/NASDAQ: OPT) announced that its wet age-related macular degeneration (wet AMD) program will be presented at the Innovate Retina Meeting on October 17, 2024, in Chicago, Illinois. Dr. David Boyer will provide an update on sozinibercept, highlighting:

  • The unmet medical need in wet AMD
  • Phase 2b trial results
  • Phase 3 program designed to assess superiority in visual acuity of the combination therapy with sozinibercept over anti-VEGF-A monotherapy

The presentation, titled 'Update on OPT-302 (sozinibercept)', is scheduled for 5:27 PM CT during Session 4: New Routes and New Molecules. Innovate Retina focuses on innovations in retina care, including AMD management, ocular imaging, gene therapy, and advances in retinal pharmacotherapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
none
Rhea-AI Summary

Opthea (ASX/NASDAQ: OPT), a clinical-stage biopharmaceutical company developing therapies for retinal diseases, has announced three key appointments as it prepares for sozinibercept Phase 3 topline data readouts in 2025:

1. Dr. Parisa Zamiri as Chief Medical Officer (CMO), overseeing clinical development, regulatory affairs, and medical affairs.

2. Tom Reilly as Chief Financial Officer (CFO), bringing over 25 years of experience in finance and administration in life sciences.

3. Anand Sundaram as Vice President Marketing, with extensive commercial experience in retina and other therapeutic areas.

These appointments aim to strengthen Opthea's leadership in preparation for anticipated data readouts from the COAST trial in early Q2 2025 and the ShORe trial in mid-2025, followed by regulatory submissions globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.83%
Tags
management clinical trial
-
Rhea-AI Summary

Opthea (ASX/NASDAQ: OPT), a clinical-stage biopharmaceutical company focusing on novel therapies for retinal diseases like wet age-related macular degeneration (wet AMD), has announced its participation in the UBS Virtual Ophthalmology Day 2024. The event is scheduled for October 2, 2024.

Key details of Opthea's participation include:

  • A fireside chat on Wednesday, October 2, 2024, at 4:00 PM ET
  • CEO Frederic Guerard, PharmD, will be the presenter
  • One-on-one investor meetings will be available
  • A webcast link is provided for access to the fireside chat

The webcast will also be accessible through the 'Events & Presentations' section of Opthea's Investor Relations webpage at www.opthea.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.52%
Tags
conferences
-
News
Rhea-AI Summary

Opthea (ASX/NASDAQ: OPT), a clinical-stage biopharmaceutical company developing therapies for retinal diseases, has been added to the S&P/ASX 300 Index effective September 23, 2024. This inclusion reflects the company's strengthened balance sheet following a financing round in July 2024 and the completion of enrollment for its Phase 3 wet AMD program with nearly 2,000 patients.

CEO Frederic Guerard highlighted that joining the index may diversify Opthea's institutional shareholder base as the company progresses towards anticipated topline data readouts from its COAST and ShORe trials in Q2 and mid-2025, respectively. The company is also preparing for a potential US FDA approval and product launch.

The S&P/ASX 300 Index measures the performance of 300 of Australia's largest securities by float-adjusted market capitalization, encompassing large-cap, mid-cap, and small-cap components.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
none
Rhea-AI Summary

Opthea (ASX/NASDAQ: OPT) has successfully completed its drug substance Process Performance Qualification (PPQ) campaign for sozinibercept, a potential treatment for wet age-related macular degeneration (wet AMD). The campaign involved producing three consecutive commercial-scale drug substance batches, validating Opthea's manufacturing process. This achievement is a significant milestone towards a potential Biologics License Application (BLA) filing for sozinibercept in wet AMD.

CEO Fred Guerard emphasized that this success demonstrates the company's ability to consistently manufacture quality drug substance at commercial scale, a important component for the BLA Chemistry, Manufacturing and Controls (CMC) module. Opthea is now well-positioned to supply its planned drug product PPQ campaign and initial launch materials. A progress update on the drug product PPQ campaign is expected in early 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.58%
Tags
none

FAQ

What is the current stock price of Opthea (OPT)?

The current stock price of Opthea (OPT) is $3.41 as of July 1, 2025.

What is the market cap of Opthea (OPT)?

The market cap of Opthea (OPT) is approximately 524.8M.
Opthea Ltd

Nasdaq:OPT

OPT Rankings

OPT Stock Data

524.82M
153.88M
3.68%
0.28%
Biotechnology
Healthcare
Link
Australia
South Yarra